Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026)
Valneva SE's (VALN) quarterly Other Non-Current Liabilities came in at $14.4 million in Q1 2026, up 140.16% year-on-year from $6.0 million in Q1 2025, and up 6.4% quarter-over-quarter from $13.6 million in Q4 2025.
Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $14.4 million for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $14.4 million, up 140.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.4 million (up 140.16% YoY), and the FY2025 annual result was $13.6 million, up 2226.08% from the prior year.
- Other Non-Current Liabilities came in at $14.4 million for Q1 2026 at Valneva SE, up from $13.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $60.7 million in Q2 2022 to a low of $583453.1 in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $10.4 million (2024), against an average of $15.0 million.
- Across the five-year window, Other Non-Current Liabilities plunged 77.31% in 2023 and jumped 2226.08% in 2025, its largest moves.
- Valneva SE's Other Non-Current Liabilities stood at $1.3 million in 2022, then decreased by 14.19% to $1.2 million in 2023, then plunged by 49.51% to $583453.1 in 2024, then soared by 2226.08% to $13.6 million in 2025, then grew by 6.4% to $14.4 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $14.4 million (Q1 2026), $13.6 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.44 Mn |
| Dec 31, 2025 | 13.57 Mn |
| Sep 30, 2025 | 12.36 Mn |
| Jun 30, 2025 | 6.62 Mn |
| Mar 31, 2025 | 6.01 Mn |
| Dec 31, 2024 | 583,453.09 |
| Sep 30, 2024 | 8.01 Mn |
| Jun 30, 2024 | 7.50 Mn |
| Mar 31, 2024 | 10.38 Mn |
| Dec 31, 2023 | 1.16 Mn |
| Sep 30, 2023 | 10.35 Mn |
| Jun 30, 2023 | 13.77 Mn |
| Mar 31, 2023 | 25.80 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 27.92 Mn |
| Jun 30, 2022 | 60.70 Mn |
| Mar 31, 2022 | 34.29 Mn |
| Dec 31, 2021 | 78,934.00 |
| Dec 31, 2020 | 85,844.87 |